NorthSea Therapeutics B.V

As the industry awaits the potential first approval of a metabolic-associated steatohepatitis (MASH) drug on 14 March, Ionis Pharmaceuticals, Inc. may have worked its way into the race to follow Ma

Late-stage development in non-alcoholic steatohepatitis (NASH) stagnated a bit in 2020 after a pair of setbacks – the US Food and Drug Administration complete response letter to Intercept for the ND

Big backing for venture capital-funded private biopharmaceutical companies has not wavered as 2021 draws to a close despite a recent slowdown in large initial public offerings by drug developers in th

BioGeneration Ventures (BGV) and Autobahn Labs recently emerged with new sources of funding for the translation of early research into drug development platforms and therapeutic candidates. Naarden, T